Chimeric antigen receptor (CAR) T cell therapy targeting glypican‐3 (GPC3) has been developed for HCC; however, clinical trials have demonstrated heterogeneous responses among patients and limited CAR‐T cell infiltration. This evidence concerns the gene GPC3 and hepatocellular carcinoma.